The fitness costs of antibiotic resistance mutations.

Melnyk AH, Wong A, Kassen R. · 2015

Read The fitness costs of antibiotic resistance mutations. by Melnyk AH, Wong A, Kassen R. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4380921.txt.

Introduction

Anita Melnyk, Alex Wong, and Rees Kassen pooled studies on the fitness costs of antibiotic resistance, in Evolutionary Applications in 2015. When bacteria gain resistance through a mutation, the change often slows their growth or weakens them in drug-free settings. Such costs decide whether resistance fades when treatment stops. The team ran a meta-analysis of studies that measured the cost of single resistance mutations across drugs and bacterial species.

On the whole, resistance mutations were costly, the pooled results showed. But the average hid real variety: several drug classes and bacterial species showed no clear cost at all. Where costs are low, resistance is more likely to linger after drug use falls. The authors call for more work on second mutations that repay the cost, since those compensations shape how resistance can be managed in clinics.

Catalog record

CREATORMelnyk AH, Wong A, Kassen R.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4380921

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The fitness costs of antibiotic resistance mutations By Anita H Melnyk, Alex Wong, Rees Kassen Published in: Evolutionary Applications DOI: 10.1111/eva.12196 ABSTRACT Antibiotic resistance is increasing in pathogenic microbial populations and is thus a major threat to public health. The fate of a resistance mutation in pathogen populations is determined in part by its fitness. Mutations that suffer little or no fitness cost are more likely to persist in the absence of antibiotic treatment. In this review, we performed a meta-analysis to investigate the fitness costs associated with single mutational events that confer resistance. Generally, these mutations were costly, although several drug classes and species of bacteria on average did not show a cost. Further investigations into the rate and fitness values of compensatory mutations that alleviate the costs of resistance will help us to better understand both the emergence and management of antibiotic resistance in clinical settings. INTRODUCTION The initial optimism accompanying the introduction of antibiotics to control infection over 60 years ago has been steadily worn down by continuing reports of antimicrobial resistance (AMR) among nearly all human-associated pathogens (Palumbi 2001; Perron et al. 2006). AMR already represents a major burden on healthcare systems around the world. Estimates of the economic burden of AMR are estimated to be at least 1.5 billion euros annually in Europe (World Health Organization 2012) and on the order of $200 million annually in Canada alone (Conly 2002), and these costs are expected to get worse with time. Widespread therapeutic and prophylactic use of antibiotics in health care and agriculture constitutes a strong and persistent selective pressure favoring the evolution of antibiotic-resistant strains, a phenomenon characterized by Hall (2004) as ‘use it and lose it’. For this reason, research has been increasingly focused on eliminating, or at least controlling, AMR once it has evolved. The most common strategy is to stop using antibiotics, the assumption being that mutations conferring resistance impose a large fitness cost in the absence of the drug. Note that fitness is taken here to be the rate of replication under prevailing environmental conditions and can be measured through competitive fitness trials or as the growth rate of the strain or population being considered. Sensitive genotypes that do not pay a cost of resistance should therefore replace resistant strains at a rate proportional to the magnitude of the cost imposed by resistance (Levin et al. 1997; Johnsen et al. 2009). Resistance mutations may be expected to impart a fitness cost because they target important biological functions in the cell (Table 1). For example, resistance to fluoroquinolones in pseudomonads can cause impaired motility (Stickland et al. 2010), and resistance to aminoglycosides can alter the structure of the ribosome (Springer et al. 2001; Holberger and Hayes 2009) and so interfere with basic cellular functions. [Table: Antibiotics included in this meta-analysis] Clinical and epidemiological evidence on the effectiveness of stopping antibiotic treatment as a strategy for reducing resistance is both limited and mixed. Clinical studies have shown that in some cases, resistant bacteria remained abundant in the population (Enne et al. 2001; Sundqvist et al. 2010) or even increased in frequency (Arason et al. 2002) despite the absence of drug, while in others the proportion of resistant bacteria within the population declined (Seppala et al. 1997; Austin et al. 1999; Bergman et al. 2004; Gottesman et al. 2009), as expected. In epidemiological studies, reducing the use of antibiotics often leads to a reduction in the frequency of resistant strains, but it rarely succeeds in eliminating them altogether (Salyers and Amabile-Cuevas 1997; Andersson 2003; Enne 2010; Johnsen et al. 2011). Evidently, the strategy of stopping the use of a drug once resistance has evolved is not always effective at eliminating resistance. The question is why? Three hypotheses could account for the persistence of AMR strains in the absence of antibiotic (Box 1; Andersson 2003; Andersson and Hughes 2010). First, genetic linkage between the resistance gene(s) of interest and selected loci may lead to genetic co-selection (Borrell et al. 2013) and prevent the elimination of resistance. Many instances of persistence in multidrug-resistant strains or plasmid-mediated resistance are likely due to this mechanism. Second, the fitness costs incurred by resistance mutations may be compensated by second-site mutations that increase fitness without compromising resistance. Such compensatory evolution has been observed in both in vitro (Levin et al. 2000), in vivo (Björkman et al. 2000), and in clinical studies (Björkholm et al. 2001; Nagaev et al. 2001; Gagneux et al. 2006; Comas et al. 2011). Third, the pleiotropic costs of resistance among mutations may be so highly variable as to sometimes include ‘no-cost’ mutations (Sander et al. 2002; Ramadhan and Hegedus 2005), those that have fitness indistinguishable from (or even greater than) their antibiotic-sensitive ancestor in the absence of antibiotic. This last hypothesis has proven challenging to evaluate because we know very little about variation in costs of resistance among different genetic targets. Previous work has shown that costs of resistance among single-step, chromosomal mutations can be highly variable (Kassen and Bataillon 2006), and the literature contains a number of reports of putatively cost-free mutations, including streptomycin resistance in the rpsL locus of Mycobacterium smegmatis (Sander et al. 2002), isoniazid resistance in katG of Mycobacterium tuberculosis using a mouse model (Pym et al. 2002) and quinolone resistance in gyrA and parC of Streptococcus pneumoniae (Gillespie et al. 2002). Box 1: Mechanisms of gaining and maintaining antibiotic resistanceProkaryotic microbes can gain resistance de novo by adaptive evolution or via horizontal gene transfer of resistance cassettes between microbes. Resistance can be maintained, in the absence of antibiotic selection, in three ways. Resistance mutations may incur no fitness costs and thus remain in the population in the absence of antibiotic selection pressure. Alternately, costs of resistance can be compensated via second-site mutations that restore organismal fitness in the absence of antibiotic selection. Finally, genetic co-selection can occur whereby there is a genetic linkage between a resistance-conferring gene and either other selected genetic markers or other selected resistance mutations to different antibiotics, thereby enabling nonselected resistance to remain within the population. To explore the nature of the variation in fitness costs among resistance mutations in more detail, we collate data from the literature on the fitness effects of single chromosomal mutational events that confer antibiotic resistance from a wide range of pathogenic bacterial species. Our objective is to examine the prevalence of so-called ‘no-cost’ resistance mutations with the aim of evaluating whether these could make a substantial contribution to the persistence of AMR (Box 2). We focus on studies that measure fitness directly through competitive assays between a strain with a resistance mutation and the isogenic strain lacking that mutation. This method is preferred over alternatives such as the measurement of population growth rates in pure culture because it is an integrated measure involving all phases of the growth cycle and can capture aspects of competition such as toxin production that may not be reflected in pure culture assays. Box 2: GlossaryCompensatory mutation: A second-site mutation that occurs after a mutation that confers resistance, which lessens or alleviates the fitness costs associated with resistance.Cross-resistance: The propensity of a genetic change that confers resistance to one drug also to affect resistance to a

Read the complete text